Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
Nuwellis (Nasdaq: NUWE) reported Q2 2025 financial results, with revenue declining to $1.7 million from $2.2 million in Q2 2024, primarily due to industry-wide sterilization vendor issues. The company's gross margin contracted to 55.5% from 67.2% year-over-year.
Key developments include expanding to 47 pediatric centers, completing a $5 million gross capital raise, and executing a manufacturing outsourcing plan to KDI Precision Manufacturing. The company reported a net loss of $12.6 million, or $60.99 per share, compared to $7.7 million loss in Q2 2024. As of June 30, 2025, Nuwellis maintained $4.5 million in cash and remained debt-free.
Nuwellis (Nasdaq: NUWE) ha comunicato i risultati finanziari del secondo trimestre 2025: i ricavi sono scesi a $1,7 milioni rispetto a $2,2 milioni nel 2掳 trimestre 2024, principalmente a causa di problemi diffusi tra i fornitori di sterilizzazione del settore. Il margine lordo si 猫 ridotto al 55,5% dal 67,2% su base annua.
Tra gli sviluppi principali figurano l'espansione a 47 centri pediatrici, il completamento di un aumento di capitale lordo di $5 milioni e l'esternalizzazione della produzione a KDI Precision Manufacturing. La societ脿 ha riportato una perdita netta di $12,6 milioni, ovvero $60,99 per azione, rispetto alla perdita di $7,7 milioni nel 2掳 trimestre 2024. Al 30 giugno 2025, Nuwellis disponeva di $4,5 milioni in cassa e non aveva debiti.
Nuwellis (Nasdaq: NUWE) inform贸 sus resultados financieros del 2T 2025: los ingresos cayeron a 1,7 millones de d贸lares desde 2,2 millones en el 2T 2024, principalmente por problemas generalizados con proveedores de esterilizaci贸n en la industria. El margen bruto se redujo al 55,5% frente al 67,2% interanual.
Entre los hitos se incluyen la expansi贸n a 47 centros pedi谩tricos, la finalizaci贸n de una colocaci贸n bruta de capital de 5 millones de d贸lares y la externalizaci贸n de la fabricaci贸n a KDI Precision Manufacturing. La compa帽铆a registr贸 una p茅rdida neta de 12,6 millones de d贸lares, o 60,99 d贸lares por acci贸n, frente a una p茅rdida de 7,7 millones en el 2T 2024. Al 30 de junio de 2025, Nuwellis contaba con 4,5 millones de d贸lares en efectivo y sin deuda.
Nuwellis (Nasdaq: NUWE)電� 2025雲� 2攵勱赴 鞁れ爜鞚� 氚滍憸頄堨姷雼堧嫟. 毵れ稖鞚� 鞐呹硠 鞝勲皹鞚� 氅戈窢 瓿店笁鞐呾泊 氍胳牅搿� 鞚疙暣 鞝勲厔 霃欔赴 $2.2 million鞐愳劀 $1.7 million鞙茧 臧愳唽頄堨溂氅�, 毵れ稖齑濎澊鞚惦鞚� 鞝勲厔 霃欔赴 雽�牍� 67.2%鞐愳劀 55.5%搿� 於曥唽霅橃棃鞀惦媹雼�.
欤检殧 雮挫毄鞙茧電� 47臧� 靻岇晞 靹柬劙搿滌潣 頇曥灔, $5 million 攴滊鞚� 齑� 鞛愲掣 臁半嫭 鞕勲, 攴鸽Μ瓿� KDI Precision Manufacturing鞙茧鞚� 鞝滌“ 鞎勳泝靻岇嫳 鞁ろ枆鞚� 鞛堨姷雼堧嫟. 須岇偓電� $12.6 million鞚� 靾滌啇鞁�(欤茧嫻 $60.99)鞚� 旮半頄堨溂氅�, 鞚措姅 2024雲� 2攵勱赴鞚� 7.7 million 雼煬 靻愳嫟瓿� 牍勱祼霅╇媹雼�. 2025雲� 6鞗� 30鞚� 旮办 Nuwellis電� $4.5 million鞚� 順勱笀鞚� 氤挫湢頃橁碃 氍挫皑鞛� 靸來儨毳� 鞙犾頃橁碃 鞛堨姷雼堧嫟.
Nuwellis (Nasdaq: NUWE) a publi茅 ses r茅sultats du 2e trimestre 2025. Le chiffre d'affaires a diminu茅 脿 1,7 million de dollars contre 2,2 millions au 2T 2024, principalement en raison de probl猫mes g茅n茅ralis茅s chez les prestataires de st茅rilisation du secteur. La marge brute s'est contract茅e 脿 55,5% contre 67,2% d'une ann茅e sur l'autre.
Parmi les faits marquants : l'expansion 脿 47 centres p茅diatriques, la r茅alisation d'une lev茅e brute de capitaux de 5 millions de dollars et la mise en place d'une externalisation de la production vers KDI Precision Manufacturing. La soci茅t茅 a enregistr茅 une perte nette de 12,6 millions de dollars, soit 60,99 dollars par action, contre une perte de 7,7 millions au 2T 2024. Au 30 juin 2025, Nuwellis disposait de 4,5 millions de dollars de liquidit茅s et 茅tait sans dette.
Nuwellis (Nasdaq: NUWE) ver枚ffentlichte die Finanzergebnisse f眉r Q2 2025. Der Umsatz sank auf 1,7 Mio. USD gegen眉ber 2,2 Mio. USD im Q2 2024, haupts盲chlich aufgrund branchenweiter Probleme mit Sterilisationsanbietern. Die Bruttomarge schrumpfte im Jahresvergleich von 67,2% auf 55,5%.
Wesentliche Entwicklungen sind der Ausbau auf 47 p盲diatrische Zentren, der Abschluss einer Brutto-Kapitalaufnahme von 5 Mio. USD sowie die Auslagerung der Fertigung an KDI Precision Manufacturing. Das Unternehmen meldete einen Nettoverlust von 12,6 Mio. USD bzw. 60,99 USD je Aktie, verglichen mit einem Verlust von 7,7 Mio. USD im Q2 2024. Zum 30. Juni 2025 verf眉gte Nuwellis 眉ber 4,5 Mio. USD in bar und war schuldenfrei.
- Expansion to 47 pediatric centers with two new additions in the Southeast US
- Successful completion of $5 million gross capital raise
- New U.S. patent granted for fluid bag design
- Company remains debt-free
- Strategic manufacturing outsourcing to KDI Precision Manufacturing
- Revenue declined 22.7% to $1.7 million year-over-year
- Gross margin contracted significantly from 67.2% to 55.5%
- Operating loss increased to $2.9 million from $2.3 million
- Net loss widened to $12.6 million from $7.7 million year-over-year
- Production disruption due to sterilization vendor issues
Insights
Nuwellis reported declining revenue and margins due to sterilization issues, with continued cash burn despite operational restructuring efforts.
Nuwellis's Q2 2025 results reveal significant financial challenges, with revenue declining
The company's cash position stands at
Strategically, Nuwellis is pivoting toward higher-potential market segments, particularly pediatric care and cardiac surgery, while setting groundwork for expansion in outpatient heart failure treatment. The addition of two new pediatric centers (bringing the total to 47) demonstrates modest traction in this focus area. The company has also outsourced manufacturing to KDI Precision Manufacturing, likely to reduce fixed costs and improve operational flexibility.
While management frames the revenue decline as temporary, the significant margin compression and widening losses suggest structural challenges beyond just the sterilization delay. The stark increase in net loss per share (from
MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company dedicated to transforming care for fluid overload patients, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.
Second Quarter 2025 and Recent Business Highlights
Nuwellis continued to advance its strategic realignment during the second quarter, sharpening focus on high-impact growth areas in pediatric and cardiac surgery care while laying the foundation for expansion in outpatient heart failure. Despite temporary revenue disruption related to an industry-wide sterilization vendor issue, the company took swift action to prioritize patient care, protect its most vulnerable populations, and ensure strong momentum entering the third quarter.
- Revenue of
$1.7 million , compared to$2.2 million in Q2 2024 - Pediatric category remains a key driver of sustained demand
- Executed a transition plan to outsource manufacturing to KDI Precision Manufacturing
- Completed a
$5 million gross capital raise during the quarter - Successfully grew to 47 pediatric centers that adopted Aquadex therapy as part of their fluid management approach with the addition of two new centers across the Southeastern United States
- Expanded IP portfolio with granting of new U.S. patent covering the fluid bag design that passively drains once full
鈥淲hile we faced a temporary headwind this quarter due to a vendor issue, our response demonstrated the strength of our operational discipline and our commitment to patients,鈥� said John Erb, Chairman of the Board and CEO of Nuwellis. 鈥淲e鈥檙e entering the second half of the year with clear priorities, a sharpened focus on our core markets, and the confidence that we鈥檙e executing on the right strategy to drive long-term growth.鈥�
Second Quarter 2025 Financial Results
Revenue for the second quarter of 2025 was
Gross margin was
Selling, general and administrative (SG&A) expenses were
Total operating expenses for the quarter were
Operating loss for the quarter was
Net loss attributable to common shareholders was
As of June 30, 2025, the company had
Conference Call and Webcast Information
Nuwellis will host a conference call and webcast today at 9:00 AM ET to discuss its first quarter results and recent business developments.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, participants may dial 1-800-245-3047 (U.S.) or 1-203-518-9765 (International) and use conference ID: NUWEQ2. A replay will be available following the event.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a commercial-stage medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company鈥檚 focus is on commercializing the Aquadex SmartFlow庐 system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minnesota, with a wholly owned subsidiary in Ireland. For more information, visit ir.nuwellis.com or follow us on LinkedIn or X.
About the Aquadex SmartFlow庐 System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding future growth and market opportunities. Forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties that could cause actual results to differ materially. These risks are detailed in the Company's filings with the Securities and Exchange Commission. Nuwellis undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
Investors:
Robert Scott
Nuwellis
Chief Financial Officer
Media Contact:
Leah McMullen
Nuwellis
Director of Communications
| 听 | |||||||
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | |||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | June 30, 2025听 | 听 | 听 | December 31, 2024听 | ||
| 听 | 听 | (Unaudited) | 听 | 听 | 听 | 听 | 听 |
| ASSETS | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Current assets | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Cash and cash equivalents | $ | 4,450 | 听 | 听 | $ | 5,095 | 听 |
| Accounts receivable | 听 | 1,193 | 听 | 听 | 听 | 1,727 | 听 |
| Inventories, net | 听 | 2,028 | 听 | 听 | 听 | 1,718 | 听 |
| Other current assets | 听 | 745 | 听 | 听 | 听 | 315 | 听 |
| Total current assets | 听 | 8,416 | 听 | 听 | 听 | 8,855 | 听 |
| Property, plant and equipment, net | 听 | 359 | 听 | 听 | 听 | 478 | 听 |
| Operating lease right-of-use asset | 听 | 404 | 听 | 听 | 听 | 510 | 听 |
| Other assets | 听 | 21 | 听 | 听 | 听 | 21 | 听 |
| TOTAL ASSETS | $ | 9,200 | 听 | 听 | $ | 9,864 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS鈥� EQUITY (DEFICIT) | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Current liabilities | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Accounts payable and accrued liabilities | $ | 3,008 | 听 | 听 | $ | 1,640 | 听 |
| Accrued compensation | 听 | 561 | 听 | 听 | 听 | 640 | 听 |
| Current portion of operating lease liability | 听 | 249 | 听 | 听 | 听 | 238 | 听 |
| Other current liabilities | 听 | 74 | 听 | 听 | 听 | 41 | 听 |
| Total current liabilities | 听 | 3,892 | 听 | 听 | 听 | 2,559 | 听 |
| Warrant liabilities | 听 | 14,074 | 听 | 听 | 听 | 468 | 听 |
| Operating lease liability | 听 | 189 | 听 | 听 | 听 | 307 | 听 |
| Total liabilities | 听 | 18,155 | 听 | 听 | 听 | 3,334 | 听 |
| Commitments and contingencies | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Mezzanine Equity Series J Convertible Preferred Stock as of June 30, 2025 and December 31, 2024, par value | 听 | 5 | 听 | 听 | 听 | 2 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Stockholders鈥� equity (deficit) | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Series A junior participating preferred stock as of June 30, 2025 and December 31, 2024, par value | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Series F convertible preferred stock as of June 30, 2025 and December 31, 2024, par value | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Series F-1 convertible preferred stock as of June 30, 2025 and December 31, 2024, par value | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Preferred stock as of June 30, 2025 and December 31, 2024, par value | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Common stock as of June 30, 2025 and December 31, 2024, par value 527,158 and 104,142, respectively | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Additional paid-in capital | 听 | 305,452 | 听 | 听 | 听 | 305,366 | 听 |
| Accumulated other comprehensive income: | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Foreign currency translation adjustment | 听 | (54 | ) | 听 | 听 | (47 | ) |
| Accumulated deficit | 听 | (314,358 | ) | 听 | 听 | (298,791 | ) |
| Total stockholders鈥� equity (deficit) | 听 | (8,960 | ) | 听 | 听 | 6,528 | 听 |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS鈥� EQUITY (DEFICIT) | $ | 9,200 | 听 | 听 | 听 | 9,864 | 听 |
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts and weighted average shares outstanding) | |||||||||||||||
| 听 | 听 | 听 | 听 | ||||||||||||
| 听 | 听 | Three months ended June 30 | Six months ended June 30 | ||||||||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Net sales | $ | 1,725 | 听 | 听 | $ | 2,194 | 听 | 听 | $ | 3,629 | 听 | 听 | $ | 4,051 | 听 |
| Cost of goods sold | 听 | 767 | 听 | 听 | 听 | 720 | 听 | 听 | 听 | 1,604 | 听 | 听 | 听 | 1,386 | 听 |
| Gross profit | 听 | 958 | 听 | 听 | 听 | 1,474 | 听 | 听 | 听 | 2,025 | 听 | 听 | 听 | 2,665 | 听 |
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Selling, general and administrative | 听 | 3,189 | 听 | 听 | 听 | 3,236 | 听 | 听 | 听 | 6,766 | 听 | 听 | 听 | 7,842 | 听 |
| Research and development | 听 | 675 | 听 | 听 | 听 | 558 | 听 | 听 | 听 | 1,225 | 听 | 听 | 听 | 1,892 | 听 |
| Total operating expenses | 听 | 3,864 | 听 | 听 | 听 | 3,794 | 听 | 听 | 听 | 7,991 | 听 | 听 | 听 | 9,734 | 听 |
| Loss from operations | 听 | (2,906 | ) | 听 | 听 | (2,320 | ) | 听 | 听 | (5,966 | ) | 听 | 听 | (7,069 | ) |
| Other income (expense), net | 听 | 10 | 听 | 听 | 听 | 6 | 听 | 听 | 听 | 17 | 听 | 听 | 听 | (95 | ) |
| Financing expense | 听 | (10,553 | ) | 听 | 听 | (5,607 | ) | 听 | 听 | (10,553 | ) | 听 | 听 | (5,607 | ) |
| Change in fair value of warrant liabilities | 听 | 900 | 听 | 听 | 听 | 198 | 听 | 听 | 听 | 940 | 听 | 听 | 听 | 720 | 听 |
| Loss before income taxes | 听 | (12,549 | ) | 听 | 听 | (7,723 | ) | 听 | 听 | (15,562 | ) | 听 | 听 | (12,051 | ) |
| Income tax expense | 听 | (4 | ) | 听 | 听 | (2 | ) | 听 | 听 | (5 | ) | 听 | 听 | (4 | ) |
| Net loss | $ | (12,553 | ) | 听 | $ | (7,725 | ) | 听 | $ | (15,567 | ) | 听 | $ | (12,055 | ) |
| Deemed dividend attributable to Series J Convertible Preferred Stock | 听 | 1 | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 2 | 听 | 听 | 听 | 541 | 听 |
| Net loss attributable to common shareholders | $ | (12,552 | ) | 听 | $ | (7,725 | ) | 听 | $ | (15,565 | ) | 听 | $ | (11,514 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Basic and diluted loss per share | $ | (60.99 | ) | 听 | $ | (791.82 | ) | 听 | $ | (100.44 | ) | 听 | $ | (139.74 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Weighted average shares outstanding 鈥� basic and diluted | 听 | 205,839 | 听 | 听 | 听 | 9,755 | 听 | 听 | 听 | 154,991 | 听 | 听 | 听 | 86,261 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Other comprehensive loss: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Net Loss | $ | (12,553 | ) | 听 | $ | (7,725 | ) | 听 | $ | (15,567 | ) | 听 | $ | (12,055 | ) |
| Foreign currency translation adjustments | $ | (5 | ) | 听 | $ | (2 | ) | 听 | $ | (7 | ) | 听 | $ | (11 | ) |
| Total comprehensive loss | $ | (12,558 | ) | 听 | $ | (7,727 | ) | 听 | $ | (15,574 | ) | 听 | $ | (12,066 | ) |
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) | |||||||
| 听 | 听 | 听 | |||||
| 听 | 听 | Six months ended June 30 | |||||
| 听 | 听 | 2025 | 听 | 听 | 2024 | ||
| Operating Activities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Net loss | $ | (15,567 | ) | 听 | $ | (12,055 | ) |
| Adjustments to reconcile net loss to cash flows used in operating activities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Depreciation and amortization | 听 | 123 | 听 | 听 | 听 | 151 | 听 |
| Stock-based compensation expense | 听 | 84 | 听 | 听 | 听 | 273 | 听 |
| Change in fair value of warrant liabilities | 听 | (940 | ) | 听 | 听 | (720 | ) |
| Financing expense | 听 | 10,553 | 听 | 听 | 听 | 5,607 | 听 |
| Changes in operating assets and liabilities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Accounts receivable | 听 | 534 | 听 | 听 | 听 | 659 | 听 |
| Inventory, net | 听 | (310 | ) | 听 | 听 | 30 | 听 |
| Other current assets | 听 | (430 | ) | 听 | 听 | (395 | ) |
| Other assets and liabilities | 听 | 32 | 听 | 听 | 听 | 5 | 听 |
| Accounts payable and accrued expenses | 听 | 1,288 | 听 | 听 | 听 | 829 | 听 |
| Net cash used in operating activities | 听 | (4,633 | ) | 听 | 听 | (5,616 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Investing Activities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Purchases of property and equipment | 听 | (4 | ) | 听 | 听 | (53 | ) |
| Net cash used in investing activities | 听 | (4 | ) | 听 | 听 | (53 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Financing Activities: | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Issuance of common stock and warrants from offering, net | 听 | 3,999 | 听 | 听 | 听 | 2,403 | 听 |
| Proceeds from the exercise of Series J Convertible Preferred Warrants | 听 | 鈥� | 听 | 听 | 听 | 500 | 听 |
| Net cash provided by financing activities | 听 | 3,999 | 听 | 听 | 听 | 2,903 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Effect of exchange rate changes on cash | 听 | (7 | ) | 听 | 听 | (11 | ) |
| Net decrease in cash and cash equivalents | 听 | (645 | ) | 听 | 听 | (2,777 | ) |
| Cash and cash equivalents - beginning of period | 听 | 5,095 | 听 | 听 | 听 | 3,800 | 听 |
| Cash and cash equivalents - end of period | $ | 4,450 | 听 | 听 | $ | 1,023 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Supplemental cash flow information | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Issuance of Series J Preferred Stock for exercise of Warrants | $ | 鈥� | 听 | 听 | $ | 1,857 | 听 |
| Issuance of Common Stock for conversion of Series J Preferred Stock | $ | 鈥� | 听 | 听 | $ | 1,535 | 听 |
| Issuance of Common Stock for conversion of Series F-1 Preferred Stock | $ | 1,100 | 听 | 听 | $ | 鈥� | 听 |
| Deemed dividend on Series J Preferred Stock | $ | 2 | 听 | 听 | $ | (541 | )听 |
| Common stock offering costs included in prepaids | $ | 鈥� | 听 | 听 | $ | 306 | 听 |
FAQ
What were Nuwellis (NUWE) Q2 2025 earnings results?
How much cash does Nuwellis (NUWE) have as of Q2 2025?
What caused Nuwellis (NUWE) revenue decline in Q2 2025?
How many pediatric centers use Nuwellis (NUWE) Aquadex therapy?
What strategic changes did Nuwellis (NUWE) implement in Q2 2025?
